Boshi Huang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8255109/publications.pdf

Version: 2024-02-01

55 papers	1,440 citations	304743 22 h-index	345221 36 g-index
58 all docs	58 docs citations	58 times ranked	1536 citing authors

#	Article	IF	Citations
1	Newly Emerging Strategies in Antiviral Drug Discovery: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Anniversary. Molecules, 2022, 27, 850.	3.8	15
2	Teaching an old dog new tricks: Drug discovery by repositioning natural products and their derivatives. Drug Discovery Today, 2022, 27, 1936-1944.	6.4	28
3	Rational Design, Chemical Syntheses, and Biological Evaluations of Peripherally Selective Mu Opioid Receptor Ligands as Potential Opioid Induced Constipation Treatment. Journal of Medicinal Chemistry, 2022, 65, 4991-5003.	6.4	3
4	Design, Synthesis, and Biological Evaluation of NAP Isosteres: A Switch from Peripheral to Central Nervous System Acting Mu-Opioid Receptor Antagonists. Journal of Medicinal Chemistry, 2022, 65, 5095-5112.	6.4	6
5	Design, Synthesis, and Antisickling Investigation of a Nitric Oxide-Releasing Prodrug of 5HMF for the Treatment of Sickle Cell Disease. Biomolecules, 2022, 12, 696.	4.0	4
6	Design, synthesis, and biological evaluation of piperidinylâ€substituted [1,2,4]triazolo[1,5â€a]pyrimidine derivatives as potential antiâ€HIVâ€1 agents with reduced cytotoxicity. Chemical Biology and Drug Design, 2021, 97, 67-76.	3.2	16
7	Design of bivalent ligands targeting putative GPCR dimers. Drug Discovery Today, 2021, 26, 189-199.	6.4	33
8	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp3 values and favorable drug-like properties. European Journal of Medicinal Chemistry, 2021, 213, 113051.	5.5	15
9	Verifying the role of 3-hydroxy of 17-cyclopropylmethyl-4,5Îµ-epoxy-3,14Î²-dihydroxy-6Î²-[(4â€²-pyridyl) carboxamido]morphinan derivatives via their binding affinity and selectivity profiles on opioid receptors. Bioorganic Chemistry, 2021, 109, 104702.	4.1	5
10	Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity. Journal of Medicinal Chemistry, 2021, 64, 7702-7723.	6.4	8
11	Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies. Journal of Medicinal Chemistry, 2021, 64, 13604-13621.	6.4	10
12	Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 NNRTIs. Acta Pharmaceutica Sinica B, 2020, 10, 878-894.	12.0	39
13	Effective and Versatile Synthesis of Ginkgotoxin and Its 4â€²-O-Derivatives through Regioselective 4â€²-O-Alkylation and 4â€²-O-Chlorination of 3,5â€²-O-Dibenzylpyridoxine. SynOpen, 2020, 04, 51-54.	1.7	1
14	VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions. Scientific Reports, 2020, 10, 20277.	3.3	14
15	Discovery of potential dual-target prodrugs of HIV-1 reverse transcriptase and nucleocapsid protein 7. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127287.	2.2	3
16	Medicinal chemistry strategies of targeting HIV-1 capsid protein for antiviral treatment. Future Medicinal Chemistry, 2020, 12, 1281-1284.	2.3	14
17	Structural elucidation and in vivo anti-arthritic activity of Î²-amyrin and polpunonic acid isolated from the root bark of Ziziphus abyssinica HochstEx. A Rich (Rhamnaceae). Bioorganic Chemistry, 2020, 98, 103744.	4.1	14
18	Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors. Drug Discovery Today, 2020, 25, 1682-1692.	6.4	13

#	Article	IF	Citations
19	Discovery of piperidine-substituted thiazolo[5,4-d]pyrimidine derivatives as potent and orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitors. Communications Chemistry, 2019, 2, .	4.5	24
20	Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles. Journal of Medicinal Chemistry, 2019, 62, 2083-2098.	6.4	66
21	First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1348-1351.	2.2	13
22	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery. ACS Medicinal Chemistry Letters, 2018, 9, 370-375.	2.8	28
23	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus. European Journal of Medicinal Chemistry, 2018, 151, 339-350.	5.5	68
24	Design, synthesis and biological evaluation of tacrine-1,2,3-triazole derivatives as potent cholinesterase inhibitors. MedChemComm, 2018, 9, 149-159.	3.4	55
25	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant. Journal of Medicinal Chemistry, 2018, 61, 6379-6397.	6.4	46
26	Inhibitors of Influenza Virus Polymerase Acidic (PA) Endonuclease: Contemporary Developments and Perspectives. Journal of Medicinal Chemistry, 2017, 60, 3533-3551.	6.4	60
27	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants. Journal of Medicinal Chemistry, 2017, 60, 4424-4443.	6.4	79
28	Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays. Bioorganic and Medicinal Chemistry, 2017, 25, 4397-4406.	3.0	23
29	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs. European Journal of Medicinal Chemistry, 2017, 140, 383-391.	5.5	12
30	Novel diaryltriazines with a picolinonitrile moiety as potent HIV-1 RT inhibitors: a patent evaluation of WO2016059647(A2). Expert Opinion on Therapeutic Patents, 2017, 27, 9-15.	5.0	9
31	Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement. European Journal of Medicinal Chemistry, 2017, 126, 190-201.	5.5	17
32	The development of an effective synthetic route of lesinurad (RDEA594). Chemistry Central Journal, 2017, 11, 86.	2.6	11
33	An improved synthesis approach of the HIV-1 inhibitor RDEA427, a pyrrolo[2,3-d]pyrimidine derivative. Arkivoc, 2017, 2016, 45-51.	0.5	3
34	Design, Synthesis, and Biological Evaluation of Novel 2-(Pyridin-3-yloxy)acetamide Derivatives as Potential Anti-HIV-1 Agents. Chemical Biology and Drug Design, 2016, 87, 283-289.	3.2	8
35	Design, synthesis, and biological evaluation of novel 5â€Alkylâ€6â€Adamantylmethylpyrimidinâ€4(3H)â€ones as <scp>HIV</scp>â€1 nonâ€nucleoside reverseâ€transcriptase inhibitors. Chemical Biology and Drug Design, 2016, 88, 380-385.	3.2	2
36	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket. European Journal of Medicinal Chemistry, 2016, 121, 352-363.	5.5	27

#	Article	IF	Citations
37	First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via â€˜privileged scaffoldâ€™ refining approach. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5182-5186.	2.2	33
38	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach. Bioorganic and Medicinal Chemistry, 2016, 24, 4424-4433.	3.0	12
39	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles. Journal of Medicinal Chemistry, 2016, 59, 7991-8007.	6.4	107
40	Arylazolyl(azinyl)thioacetanilides: Part 19: Discovery of Novel Substituted Imidazo[4,5â€b]pyridinâ€2â€ylthioacetanilides as Potent HIV NNRTIs Via a Structureâ€based Bioisosterism Approach. Chemical Biology and Drug Design, 2016, 88, 241-253.	3.2	12
41	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket. European Journal of Medicinal Chemistry, 2016, 115, 53-62.	5.5	21
42	Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1. Expert Opinion on Therapeutic Patents, 2016, 26, 281-289.	5.0	21
43	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket. European Journal of Medicinal Chemistry, 2016, 109, 294-304.	5.5	28
44	Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities. European Journal of Medicinal Chemistry, 2016, 114, 65-78.	5.5	30
45	Discovery of bioactive molecules from CuAAC click-chemistry-based combinatorial libraries. Drug Discovery Today, 2016, 21, 118-132.	6.4	138
46	Medicinal chemistry insights in the discovery of novel LSD1 inhibitors. Epigenomics, 2015, 7, 1379-1396.	2.1	42
47	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: Design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines. European Journal of Medicinal Chemistry, 2015, 93, 330-337.	5.5	41
48	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: Optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches. European Journal of Medicinal Chemistry, 2015, 92, 754-765.	5.5	76
49	Synthesis and Biological Evaluation of a Series of 2â€((1â€substitutedâ€1Hâ€1,2,3â€triazolâ€4â€yl)methylthio)â€6â€(naphthalenâ€1â€ylmethyl)pyrimidinâ€4(3H)â€one Potential <scp>HIV</scp>â€1 Inhibitors. Chemical Biology and Drug Design, 2015, 86, 614-618.	3.2	11
50	Synthesis and Preliminary Antiviral Activities of Piperidineâ€substituted Purines against <scp>HIV</scp> and Influenza A/H1N1 Infections. Chemical Biology and Drug Design, 2015, 86, 568-577.	3.2	17
51	Design, Synthesis, and Biological Evaluation of Novel 4â€Aminopiperidinylâ€linked 3,5â€Disubstitutedâ€1,2,6â€thiadiazineâ€1,1â€dione Derivatives as <scp>HIV</scp>â€1 <scp>NNRTI</scp>s. Chemical Biology and Drug Design, 2015, 86, 107-113.	3.2	6
52	Novel fluorine-containing DAPY derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2014072419. Expert Opinion on Therapeutic Patents, 2015, 25, 1477-1486.	5.0	8
53	Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities. Expert Opinion on Drug Discovery, 2015, 10, 1271-1281.	5.0	9
54	Discovery of small molecular inhibitors targeting HIV-1 gp120â€“CD4 interaction drived from BMS-378806. European Journal of Medicinal Chemistry, 2014, 86, 481-490.	5.5	25

#	Article	IF	Citations
55	Facile Synthesis of Derivatives of 1,1,3â€Trioxoâ€2H,4Hâ€pyrrolo[1,2â€b][1,2,4,6]thiatriazine; A New Heterocyclic System. Heteroatom Chemistry, 2013, 24, 495-501.	0.7	5